TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12428-12439

  Wang, Kun ^a,b   Liu, Tiantian ^c   Ge, Nan ^d   Liu, Li ^e   Yuan, Xiaotian ^b   Liu, Jikai ^a   Kong, Feng ^d   Wang, Chang ^b   Ren, Hongbo ^a   Yan, Keqiang ^a   Hu, Sanyuan ^a   Xu, Zhonghua ^a   Björkholm, Magnus ^b   Fan, Yidong ^a   Zhao, Shengtian ^d   Liu, Cheng ^a   Xu, Dawei ^b,d  

^a SHANDONG UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

Cancer biomarkers; Promoter mutations; Telomerase; TERT; UTUC

Indexed keywords

BIOLOGICAL MARKER; CYSTEINE; TELOMERASE REVERSE TRANSCRIPTASE; THREONINE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPETITIVE ALLELE SPECIFIC TAQMAN POLYMERASE CHAIN REACTION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; GENE MUTATION; HUMAN; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TRANSITIONAL CELL CARCINOMA; URINALYSIS; VERY ELDERLY; GENETICS; KIDNEY PELVIS; KIDNEY TUMOR; MUTATION; NEOPLASM METASTASIS; PATHOLOGY; PROCEDURES; URETER TUMOR; URINE;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SENSITIVITY AND SPECIFICITY; TELOMERASE; URETERAL NEOPLASMS;

EID: 84920046106     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2660     Document Type: Article

References (32)

1. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012; 498:135-146.
2. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011; 21:349-353.
3. Kong F, Zheng C, Xu D. Telomerase as a "stemness" enzyme. Sci China Life Sci. 2014; 57:564-570.
4. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014; 24:30-37.
5. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339:959-961.
6. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339:957-959.
7. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. Eur Urol. 2014; 65:360-366.
8. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2014; 65:367-368.
9. Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H, Yan K, Hu S, Björkholm, Fan Y, Xu D. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget. 2014; 5:1829-1836.
10. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol. 2014; 65:274-277.
11. Liu X, Wu G, Hartmann C, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and brain gliobastoma. Cell Cycle. 2013; 12:1637-1638.
12. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110:6021-6026.
13. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013; 110:17426-17431.
14. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Salle F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene. 2014; 33:3748-3752.
15. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014; 5:1515-1525.
16. Xie H, Liu T, Wang N, Björnhagen V, Höög A, Larsson C, Lui WO, Xu D. TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma. Oncotarget. 2014; 5:10048-10057.
17. Liu T, Wang N, Cao J, Dinets A, Sofiadis A, Zedenius J, Larsson C, Xu D. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014; 33:4978-4984.
18. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C, Xu D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014; 120:2965-2979.
19. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013; 63:1059-1071.
20. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011; 8:440-447.
21. Nakanishi K, Hiroi S, Kawai T, Aida S, Kasamatsu H, Aurues T, Ikeda T. Expression of telomerase catalytic subunit (hTERT) mRNA does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Mod Pathol. 2001; 14:1073-1078.
22. Thierry AR Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014; 20:430-435.
23. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009; 55:650-657.
24. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 2002; 21:3130-3138.
25. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 2008; 18:725-732.
26. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaBdependent transcription. Faseb J. 2013; 27:4375-4383.
27. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK. Telomerase directly regulates NF-kappaB-dependent transcription. Nat Cell Biol. 2012; 14:1270-1281.
28. Luiten RM, Pene J, Yssel H, Spits H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood. 2003; 101:4512-4519.
29. Saretzki G. Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress. Curr Pharm Des. 2014; DOI: 10.2174/1381612820666140630095606.
30. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H, Birch-Machin MA, von Zglinicki T, Saretzki G. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci. 2008; 121:1046-1053.
31. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Bjorkholm M, Jia J, Xu D. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013; 32:4203-4213.
32. Lopez-Beltran A, Bassi P, Pavone-Macaluso M and Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004; 45:257-266.